Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman, Michael S. Lawrence, Douglas Voet et al. · Nature · 2012
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Cited by 3,967 works. doi:10.1038/nature11404 Open-access PDF
Authors
- Peter S. Hammerman
- Michael S. Lawrence
- Douglas Voet
- Rui Jing
- Kristian Cibulskis
- Andrey Sivachenko
- Petar Stojanov
- Aaron McKenna
- Eric S. Lander
- Gad A. Getz
- Marcin Imielinski
- Elena Helman
- BRYAN HERNANDEZ
- Nam H. Pho
- Matthew M. Meyerson
- Gordon Saksena
- Andrew D. Cherniack
- Stephen E Schumacher
- Barbara Tabak
- Scott L. Carter
References
- Hallmarks of Cancer: The Next Generation
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Integrated genomic analyses of ovarian carcinoma
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Somatic mutations affect key pathways in lung adenocarcinoma
- The landscape of somatic copy-number alteration across human cancers